SAN DIEGO, July 31, 2020 / PRNewswire / – Biotech Table, Developer of an affordable and easy-to-use portable testing platform for infectious disease diagnosis, he announced today that he has won a contract of up to $15.4 million from the National Rapid Diagnostic Acceleration Program (RADx) of the Institutes of Health (NIH) for his Accula ™ SARV-2 test, which provides COVID-19 diagnostic effects in 30 minutes at the point of service (POC). The RADx program created to expand diversity and increase the availability of SARS-CoV-2 diagnostic tests, a must-have for Americans to safely combine, adding in the workplace, in schools, and in many places of life.
“This is a vital step,” said Bruce Tromberg, Ph.D., Director of the National Institute of Biomedical Imaging and Bioengineering and Head of RADx Tech, one of the 4 factors of the NIH RADx initiative. “This will exponentially increase the U.S.’s testing capacity. The revolutionary technologies emerging from our RADx portfolio will indicate public aptitude measures to prevent the spread of the virus and leave us more supplied to fight long-term pathogens and other diseases.” This assignment is supported by the NIH Rapid Acceleration of Diagnostics (RADx) program and has been funded in whole or in federally invested components of the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Health And Human Services Decomposer, under Contract No. 75N92020C00014.
Through a rigorous and immediate review process, the RADx program provides an independent assessment of technologies and evolutionary potential. To date, more than 650 proposals have been submitted, seven of which accelerated to RADx Phase 2, which is the last step in the process. Test technologies (such as the Accula ™ SARS-CoV-2 test) that move to Phase 2 get an appropriate raDx program budget to enable full clinical deployment in an accelerated time frame, as well as technical, advertising and production support.
One of the goals of the RADx initiative is to expand SARS-CoV-2 detection capacity to approximately 2% of the U.S. population (6 million people) as of December this year, from 520,000 to 823,000 tests consistent with the day at the start of July. Technologies that decrease the footprint of the installation, decrease the complexity of the tests and provide quick effects are especially interesting.
The Accula SARS-CoV-2 check is a visual reading check that is opposed to the generation of transcription polymer network reaction (RT-PCR) to trip over SARS-CoV-2 nasal samples. Accula SARS-CoV-2 verification is easy to use, fits the palm of your hand and offers lab-quality effects in approximately 30 minutes. Its compact design is ideal for safe use in the air, as it adds transient detection facilities, back-to-work initiatives, hospitals, clinics and long-term nursing facilities.
The generation of Mesa Biotech evolved in the National Laboratory of Los Alamos, with the support of grants from the NIH of the National Institute of Allergy and Infectious Diseases (NIAID) and the Western Regional Centers for Excellence in Biodefense and Emerging Infectious Diseases programs. The company earned the U.S. Health and Human Services investment. To extend your SARS-CoV-2 verification and U.S. Food and Drug Administration emergency use authorization. In March of this year. Since its inception, the company has focused on the generation adapted to emergency defense and immediate deployment in opposition to SARS, Ebola and other emerging infectious diseases. Mesa Biotech’s platform has been specially designed for outdoor use in the laboratory to enable immediate responses to global pandemics, such as COVID-19.
About Mesa Biotech Inc. Mesa Biotech designs, develops, manufactures and markets next-generation immediate molecular diagnostic tests, providing incredible diagnostic functionality from PCR amplification of nucleic acids to the point of service. Mesa Biotech’s Accula ™ Flu A/Flu B and RSV tests have been CE-marked in the EU and 510 (k) and CLIA (Clinical Laboratory Improvement Amendments) from the U.S. Food and Drug Administration (FDA). Both products are distributed in the United States through Sekisui Diagnostics with the Silaris ™ logo. Mesa Biotech has also concluded a number of strategic distribution agreements in Europe and Asia. For more information, https://www.mesabiotech.com.
Contacts:
President and CEO